Moderna is set to release the full phase 3 data this weekend for its experimental cancer vaccine. The company is betting on customized messenger RNA technology to treat melanoma and potentially other cancers. The project extends the technology Moderna used to develop its COVID-19 vaccine. The stock is among the year’s strongest performers, increasing the stakes for the upcoming results.
Source: Read the original article
Disclaimer: this content is for information purposes only and is not financial advice. Cryptocurrencies are highly volatile: you may lose all of your capital. Always do your own research. Legal notice
